Multi-center, pragmatic, cluster-randomized, controlled trial of standardized peritoneal dialysis (PD) training versus usual care on PD-related infections (the TEACH-PD trial): trial protocol.
Cluster randomized controlled trial
Competency assessment
Cost-effectiveness
Outcomes
Patient education
Peritoneal dialysis
Peritonitis
Standardized training
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
14 Nov 2023
14 Nov 2023
Historique:
received:
30
05
2023
accepted:
07
10
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
epublish
Résumé
Peritoneal dialysis (PD)-related infections, such as peritonitis, exit site, and tunnel infections, substantially impair the sustainability of PD. Accordingly, PD-related infection is the top-priority research outcome for patients and caregivers. While PD nurse trainers teach patients to perform their own PD, PD training curricula are not standardized or informed by an evidentiary base and may offer a potential approach to prevent PD infections. The Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes (TEACH-PD) trial evaluates whether a standardized training curriculum for PD nurse trainers and incident PD patients based on the International Society for Peritoneal Dialysis (ISPD) guidelines reduces PD-related infections compared to usual training practices. The TEACH-PD trial is a registry-based, pragmatic, open-label, multi-center, binational, cluster-randomized controlled trial. TEACH-PD will recruit adults aged 18 years or older who have not previously undergone PD training at 42 PD treatment units (clusters) in Australia and New Zealand (ANZ) between July 2019 and June 2023. Clusters will be randomized 1:1 to standardized TEACH-PD training curriculum or usual training practice. The primary trial outcome is the time to the first occurrence of any PD-related infection (exit site infection, tunnel infection, or peritonitis). The secondary trial outcomes are the individual components of the primary outcome, infection-associated catheter removal, transfer to hemodialysis (greater than 30 days and 180 days), quality of life, hospitalization, all-cause death, a composite of transfer to hemodialysis or all-cause death, and cost-effectiveness. Participants are followed for a minimum of 12 months with a targeted average follow-up period of 2 years. Participant and outcome data are collected from the ANZ Dialysis and Transplant Registry (ANZDATA) and the New Zealand Peritoneal Dialysis (NZPD) Registry. This protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines. TEACH-PD is a registry-based, cluster-randomized pragmatic trial that aims to provide high-certainty evidence about whether an ISPD guideline-informed standardized PD training curriculum for PD nurse trainers and adult patients prevents PD-related infections. ClinicalTrials.gov NCT03816111. Registered on 24 January 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Peritoneal dialysis (PD)-related infections, such as peritonitis, exit site, and tunnel infections, substantially impair the sustainability of PD. Accordingly, PD-related infection is the top-priority research outcome for patients and caregivers. While PD nurse trainers teach patients to perform their own PD, PD training curricula are not standardized or informed by an evidentiary base and may offer a potential approach to prevent PD infections. The Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes (TEACH-PD) trial evaluates whether a standardized training curriculum for PD nurse trainers and incident PD patients based on the International Society for Peritoneal Dialysis (ISPD) guidelines reduces PD-related infections compared to usual training practices.
METHODS
METHODS
The TEACH-PD trial is a registry-based, pragmatic, open-label, multi-center, binational, cluster-randomized controlled trial. TEACH-PD will recruit adults aged 18 years or older who have not previously undergone PD training at 42 PD treatment units (clusters) in Australia and New Zealand (ANZ) between July 2019 and June 2023. Clusters will be randomized 1:1 to standardized TEACH-PD training curriculum or usual training practice. The primary trial outcome is the time to the first occurrence of any PD-related infection (exit site infection, tunnel infection, or peritonitis). The secondary trial outcomes are the individual components of the primary outcome, infection-associated catheter removal, transfer to hemodialysis (greater than 30 days and 180 days), quality of life, hospitalization, all-cause death, a composite of transfer to hemodialysis or all-cause death, and cost-effectiveness. Participants are followed for a minimum of 12 months with a targeted average follow-up period of 2 years. Participant and outcome data are collected from the ANZ Dialysis and Transplant Registry (ANZDATA) and the New Zealand Peritoneal Dialysis (NZPD) Registry. This protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.
DISCUSSION
CONCLUSIONS
TEACH-PD is a registry-based, cluster-randomized pragmatic trial that aims to provide high-certainty evidence about whether an ISPD guideline-informed standardized PD training curriculum for PD nurse trainers and adult patients prevents PD-related infections.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT03816111. Registered on 24 January 2019.
Identifiants
pubmed: 37964367
doi: 10.1186/s13063-023-07715-0
pii: 10.1186/s13063-023-07715-0
pmc: PMC10647147
doi:
Banques de données
ClinicalTrials.gov
['NCT03816111']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
730Subventions
Organisme : National Health and Medical Research Council
ID : APP1170238
Organisme : National Health and Medical Research Council
ID : APP1092957
Organisme : Health Research Council of New Zealand
ID : 19/290
Informations de copyright
© 2023. Crown.
Références
Perit Dial Int. 2011 Nov-Dec;31(6):651-62
pubmed: 21719685
Kidney Int. 2022 Dec;102(6):1222-1227
pubmed: 35926657
Perit Dial Int. 2015 Jul-Aug;35(4):406-20
pubmed: 25082840
Nephrol Dial Transplant. 2017 Jun 01;32(6):1018-1023
pubmed: 28472525
Blood Purif. 2021;50(4-5):662-666
pubmed: 33626546
Perit Dial Int. 2019 Mar-Apr;39(2):134-141
pubmed: 30661004
J Am Soc Nephrol. 2012 Aug;23(8):1398-405
pubmed: 22626818
Perit Dial Int. 2016 11-12;36(6):592-605
pubmed: 26917664
Chirurgia (Bucur). 2018 Sept-Oct;113(5):611-624
pubmed: 30383988
Am J Kidney Dis. 2019 Jul;74(1):101-110
pubmed: 30799030
Perit Dial Int. 2016 9-10;36(5):509-18
pubmed: 26764341
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet Infect Dis. 2014 Jan;14(1):23-30
pubmed: 24119840
Perit Dial Int. 2019 Sep-Oct;39(5):409-413
pubmed: 31501291
JAMA Intern Med. 2019 Nov 01;179(11):1537-1542
pubmed: 31498398
BMC Nephrol. 2017 Jun 5;18(1):186
pubmed: 28583107
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Nephrol Dial Transplant. 2016 Feb;31(2):214-22
pubmed: 26908816
Perit Dial Int. 2017 Mar-Apr;37(2):141-154
pubmed: 28360365
Nephrology (Carlton). 2018 Mar;23(3):259-263
pubmed: 28042933
J Am Soc Nephrol. 2016 Nov;27(11):3238-3252
pubmed: 27339663
Int J Nephrol Renovasc Dis. 2018 Jun 11;11:173-186
pubmed: 29928142
Health Qual Life Outcomes. 2016 Sep 20;14(1):133
pubmed: 27644755
Perit Dial Int. 2022 Mar;42(2):110-153
pubmed: 35264029
Clin Kidney J. 2019 Feb 26;12(5):702-720
pubmed: 31583095
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Perit Dial Int. 2009 May-Jun;29(3):297-302
pubmed: 19458302
Perit Dial Int. 2011 Nov-Dec;31(6):614-30
pubmed: 21880990
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Sci Rep. 2019 Apr 11;9(1):5905
pubmed: 30976069
Perit Dial Int. 2020 Mar;40(2):153-163
pubmed: 32063194
Adv Perit Dial. 2017 Jan;33(2017):18-21
pubmed: 29668425
Perit Dial Int. 2017 Nov-Dec;37(6):639-647
pubmed: 28765167
Nephrology (Carlton). 2022 May;27(5):391-403
pubmed: 35060223